COMPASS Pathways Revenue and Competitors

Westminster, UK

Location

#3347

Growjo Ranking

Estimated Revenue & Valuation

  • COMPASS Pathways's estimated annual revenue is currently $51.1M per year.(i)
  • COMPASS Pathways's estimated revenue per employee is $234,330
  • COMPASS Pathways's current valuation is $747M. (January 2022)

Employee Data

  • COMPASS Pathways has 218 Employees.(i)
  • COMPASS Pathways grew their employee count by 25% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.6M5233%N/AN/A
#2
$33.2M12321%N/AN/A
#3
$21.9M81-39%N/AN/A
#4
$37.3M1385%N/AN/A
#5
$25.1M933%N/AN/A
#6
$6.9M32-22%N/AN/A
#7
$210.6M62428%N/AN/A
#8
$69.2M2339%N/AN/A
#9
$23.2M866%N/AN/A
#10
$28.6M106-1%N/AN/A
Add Company

COMPASS Pathways is a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first major initiative is developing psilocybin therapy through late-stage clinical trials in the EU and US for patients with treatment-resistant depression. We are developing psychoactive care pathways based on advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.

keywords:N/A

N/A

Total Funding

218

Number of Employees

$51.1M

Revenue (est)

25%

Employee Growth %

$747M

Valuation

N/A

Accelerator

COMPASS Pathways News

2022-04-19 - COMPASS Pathways partners with One Mind to fund Rising Star ...

COMPASS Pathways plc ( CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation...

2022-04-19 - COMPASS Pathways partners with One Mind to fund Rising Star ...

London, UK – 20 April 2022. COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient...

2022-03-22 - COMPASS Pathways and partners launch The Centre for Mental ...

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based...

2021-11-09 - Largest psilocybin trial finds the psychedelic is effective in treating serious depression

Eagerly awaited results of the largest-ever study of psilocybin were announced Tuesday, with Compass Pathways revealing the psychedelic drug was highly efficacious as a therapy for treatment-resistant depression. Still, the company’s stock price dropped 16.4% by the close of trading, perhaps bec ...

2021-11-09 - COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

Largest randomised, controlled, double-blind psilocybin therapy study ever completed shows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support COMPASS management team to host an investor conference call today at 1.00pm UK (8.00am ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A21917%N/A
#2
N/A22417%N/A
#3
$51.9M2300%N/A
#4
$36.7M23060%N/A
#5
$77.8M232-5%N/A